IONIS PHARMACEUTICALS INCIONS

時価総額

$126.8億

PER

RNA標的創薬と医薬品の研究開発を行うバイオ製薬の大手。アンチセンスオリゴヌクレオチド薬や臨床試験を通じた希少疾患向け治療薬を展開。2023年1月にロイヤルティを5億ドルで売却、2024年9月に11.5百万株を公募で売却し489.1百万ドルを調達。米国を基盤に欧州や日本で臨床開発と商業化を展開。

概要財務

サマリーテーブルに戻る

	2010年 12月31日	2011年 12月31日	2012年 12月31日	2013年 12月31日	2014年 12月31日	2015年 12月31日	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net loss	-61	-85	-65	-61	-39	-88	-87	-6	274	303	-451	-29	-270	-366	-454
Depreciation	5	7	7	7	6	7	7	7	11	13	13	15	14	10	10
Amortization of right-of-use operating lease assets	-	-	-	-	-	-	-	-	-	-	2	2	5	10	10
Amortization of other assets	-	-	-	-	-	-	-	-	2	2	2	2	2	3	2
Amortization of premium (discount) on investments, net	-	-	-	-	-	-8	-7	-7	1	7	-12	-18	-7	29	38
Amortization of debt issuance costs	1	1	1	0	1	1	1	2	2	2	3	5	5	6	7
The amount of royalty payments made during the period under a royalty purchase agreement.	-	-	-	-	-	-	-	-	-	-	-	-	-	45	45
Amount of interest expense using the effective interest rate method related to the sale of future royalties.	-	-	-	-	-	-	-	-	-	-	-	-	-	68	73
Stock-based compensation expense	12	10	9	11	31	59	72	86	131	147	230	121	100	106	130
Gain on early retirement of debt	-	-	-5	-	-8	-	-4	-	-	-22	-	-9	-	13	-
Non-cash losses related to disposal of property, plant and equipment	-	-	-	-	-	-	-	-	-	-	-	-	-1	-17	-7
Loss (gain) on sale of real estate assets	-	-	-	-	-	-	-	-	-	-	-	-	150	-0	-
Loss on investments	-	-	-	-	-	-	-	-	-	-	-	1	-0	-2	-3
Non-cash losses related to other assets	-	-	-	-	-	-	-	-	-	-	2	3	2	2	3
Contracts receivable	-	-	-	-	-	-	-	-	-48	48	13	-14	-36	72	-6
Inventories	-0	2	2	2	-2	1	1	2	-1	5	1	3	-3	6	5
Other current and long-term assets	1	-1	-0	1	2	4	-2	58	29	45	10	1	25	30	26
Accounts payable	1	1	1	0	5	9	-11	2	-1	-16	-3	-6	1	8	16
Income taxes	-	-	-	-	-4	-	1	0	-1	32	-31	-1	6	-4	-2
Accrued compensation	0	2	-1	4	0	4	8	1	4	8	28	-27	10	19	2
Accrued liabilities and other current liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-6	-43
Deferred contract revenue	-	-	-	-	-	-	-	-	494	-119	-76	-83	-71	14	-157
Net cash used in operating activities	-64	-115	-	-	-	-	-	174	603	346	36	31	-274	-308	-501
Purchases of short-term investments	-	371	218	426	392	493	301	878	1,795	1,947	1,570	1,124	1,486	1,771	1,853
Proceeds from sale of short-term investments	-	489	243	173	295	420	365	557	883	1,952	1,886	1,344	989	1,585	1,769
Purchases of property, plant and equipment	13	7	1	2	8	8	7	35	14	31	35	12	16	24	45
Proceeds from sale of real estate assets	0	-	-	-	-	-	-	-	-	-	-	-	254	0	-
Acquisition of licenses and other assets, net	-	-	-	-	-	-	-	-	-	-	-	6	4	4	5
Net cash used in investing activities	24	111	-	-	-	-	-	-358	-930	-41	274	195	-263	-214	-134
Net proceeds from stock option exercises, vesting of restricted stock units, and ESPP purchases	4	4	9	63	23	25	-	23	28	120	52	12	6	49	34
Proceeds from issuance of common stock in public offering, net	-	-	-	173	-	-	-	72	-	-	-	-	-	-	489
Repayment of 0.125 percent convertible senior notes	-	-	-	-	-	-	-	-	-	-	-	62	-	-	45
Proceeds from issuance of convertible senior notes	-	-	195	-	-	-	-	-	-	110	-	-	-	-	-
1.75 percent convertible senior notes issuance costs	-	-	-	-	-	-	-	-	-	10	-	-	-	-	-
The cash inflow from the sale of future royalties under a royalty purchase agreement.	-	-	-	-	-	-	-	-	-	-	-	-	-	500	-
The cash outflow paid to third parties for transaction costs in connection with a monetization transaction of future SPINRAZA and pelacarsen royalties the Company is entitled to under collaboration and licensing agreements.	-	-	-	-	-	-	-	-	-	-	-	-	-	10	-
The cash inflow from the transfer of legal ownership of two lots of undeveloped land to a real estate investor.	-	-	-	-	-	-	-	-	-	-	-	-	-	32	-
Principal payments on mortgage debt	-	-	-	-	-	-	-	-	-	-	-	-	51	0	0
Payments of tax withholdings related to vesting of employee stock awards and exercise of employee stock options	-	-	-	-	-	-	-	-	-	19	13	17	11	-	-
Net cash provided by (used in) financing activities	5	-1	-	-	-	-	-	229	476	100	-597	246	-55	644	478
Effects of exchange rates on cash	-	-	-	-	-	-	-	-	-	-	-	-	-0	0	-0
Net increase (decrease) in cash and cash equivalents	-	-	-	-	-	-	-	-	-	-	-286	472	-593	123	-157
Interest paid	5	-	-	-	-	-	-	8	10	10	6	5	3	7	11
Income taxes paid (refunds received)	7	0	0	0	-	-	-	-	-	9	26	-	-	-	-6
Right-of-use assets obtained in exchange for lease liabilities	-	-	-	-	-	-	-	-	-	14	2	7	169	-	-
Future cash outflow to pay for purchases of fixed assets and patents that have occurred.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1